DiaMedica Therapeutics Inc.

NasdaqCM DMAC

DiaMedica Therapeutics Inc. Price to Sales Ratio (P/S) on January 14, 2025: 6.96

DiaMedica Therapeutics Inc. Price to Sales Ratio (P/S) is 6.96 on January 14, 2025, a 97.69% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

DiaMedica Therapeutics Inc. 52-week high Price to Sales Ratio (P/S) is 8.89 on December 20, 2024, which is 27.69% above the current Price to Sales Ratio (P/S).
DiaMedica Therapeutics Inc. 52-week low Price to Sales Ratio (P/S) is 2.66 on June 21, 2024, which is -61.80% below the current Price to Sales Ratio (P/S).
DiaMedica Therapeutics Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 4.58.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: DMAC

DiaMedica Therapeutics Inc.

CEO	Mr. Dietrich John Pauls MBA
IPO Date	Aug. 3, 2012
Location	United States
Headquarters	Two Carlson Parkway
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key trends

Past 5 years